APSR2026-490

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP12-012
P89
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1220702-46904-STILD_APSR2026_poster_A0_438686.pdf
Format: PDF Only
16. Interstitial Lung Disease
11

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Yusuke Tanaka * Sapporo Medical University School of Medicine Department of Respiratory Medicine and Allergology Sapporo Japan
Haruka Takenaka - Sapporo Medical University School of Medicine Department of Respiratory Medicine and Allergology Sapporo Japan
Tatsuru Ishikawa - Sapporo Medical University School of Medicine Department of Respiratory Medicine and Allergology Sapporo Japan
Kentaro Kodama - Sapporo Medical University School of Medicine Department of Respiratory Medicine and Allergology Sapporo Japan
Yuki Mori - Sapporo Medical University School of Medicine Department of Respiratory Medicine and Allergology Sapporo Japan
Satsuki Miyajima - Sapporo Medical University School of Medicine Department of Respiratory Medicine and Allergology Sapporo Japan
Atsushi Saito - Sapporo Medical University School of Medicine Department of Respiratory Medicine and Allergology Sapporo Japan
Mamoru Takahashi - Sapporo Medical University School of Medicine Department of Respiratory Medicine and Allergology Sapporo Japan
Hirotaka Nishikiori - Sapporo Medical University School of Medicine Department of Respiratory Medicine and Allergology Sapporo Japan
Koji Kuronuma - Sapporo Medical University School of Medicine Department of Respiratory Medicine and Allergology Sapporo Japan
Hirofumi Chiba - Sapporo Medical University School of Medicine Department of Respiratory Medicine and Allergology Sapporo Japan
 
 
 
 
Presenting Author Details
Yusuke
Tanaka
tanayou@sapmed.ac.jp
+819098526418
41-50
Japan
Original Research
Interim analysis of daily versus thrice-weekly single-strength trimethoprim-sulfamethoxazole prophylaxis in corticosteroid-treated interstitial lung disease
Maximum 25 words
Abstract Content
Optimal trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis for Pneumocystis jirovecii pneumonia (PCP) in corticosteroid-treated interstitial lung disease (ILD) remains uncertain. Daily single-strength TMP-SMX may be limited by adverse events. We performed an interim analysis of an ongoing randomized trial comparing daily single-strength and lower-intensity thrice-weekly single-strength TMP-SMX in ILD.
This single-center, prospective, open-label, parallel-group randomized study enrolls adults with ILD receiving corticosteroid therapy. Patients are assigned to TMP-SMX 80/400 mg once daily or 80/400 mg three times weekly on nonconsecutive days. Planned enrollment is 140. In this interim analysis, 23 patients were evaluable (daily, n=10; thrice-weekly, n=13). Time to discontinuation was analyzed using Kaplan-Meier methods and compared using the log-rank test. Grade 3 or higher adverse events and PCP occurrence were also assessed.
The cumulative discontinuation rate was numerically lower in the thrice-weekly group. Median time to discontinuation was 98 days in the daily group and was not reached in the thrice-weekly group. The hazard ratio for discontinuation with thrice-weekly versus daily TMP-SMX was 0.32 (95% confidence interval [CI] 0.06-1.66; log-rank P=0.1635). No PCP occurred in either group. One Grade 3 gastrointestinal adverse event (abdominal pain and appetite loss) occurred on treatment day 25 in the daily group, whereas no Grade 3 or higher adverse events occurred in the thrice-weekly group.
These interim data suggest that a lower-intensity thrice-weekly single-strength TMP-SMX regimen may improve treatment continuation in corticosteroid-treated ILD. Continued enrollment and follow-up are required to determine whether this regimen maintains prophylactic effectiveness while reducing toxicity.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Interstitial lung disease, Pneumocystis jirovecii pneumonia, Trimethoprim-sulfamethoxazole
maximum 3 keywords and no abbreviations, separated by commas
 
252